The methylation status of FBXW7 β-form correlates with histological subtype in human thymoma

Biochemical and Biophysical Research Communications

Volumn 377, Issue 2, 2008, Pages 685-688

  Gu, Zhaodi ^a   Mitsui, Hidetoshi ^a   Inomata, Kenichi ^a   Honda, Masako ^b   Endo, Chiaki ^b   Sakurada, Akira ^b   Sato, Masami ^c   Okada, Yoshinori ^b   Kondo, Takashi ^b   Horii, Akira ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Miyagi Cancer Center   (Japan)

Author keywords

FBXW7 form; Methylation; Thymoma

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FBXW7 BETA GENE; FEMALE; GENE INACTIVATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; METHYLATION; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; THYMOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CELL CYCLE PROTEINS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; F-BOX PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROMOTER REGIONS, GENETIC; THYMOMA; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 55549133237     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.047     Document Type: Article

References (22)

1. The Working Group on the WHO Classification on Tumours of the Lung, Pleura, Thymus and Heart. Tumours of the thymus. In: Travis W.D., Brambilla E., Müller-Hermelink H.K., and Harris C.C. (Eds). World Health Organization Classification of Tumours. Pathology and genetics. Tumours of the lung, pleura, thymus and heart. World Health Organization, Lyon (2004), IARC Press 145-247
2. Masaoka A., Monden Y., Nakahara K., and Tanioka T. Follow-up study of thymoma with special reference to their clinical stages. Cancer 48 (1981) 2485-2492
3. Rosai J., and Sobin L.H. Histological typing of tumours of the thymus. International histological classification of tumours. second ed. (1999), Springer, Berlin
4. Rena O., Papalia E., Maggi G., Oliaro A., Ruffini E., Filosso P.L., Mancuso M., Novero D., and Casadio C. World Health Organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer 50 (2005) 59-66
5. Ströbel P., Marx A., Zettl A., and Müller-Hermelink H.K. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg. Today 35 (2005) 805-811
6. Okumura M., Shiono H., Inoue M., Tanaka H., Yoon H.E., Nakagawa K., Matsumura A., Ohta M., Iuchi K., and Matsuda H. Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to World Health Organization histologic classification system. J. Surg. Oncol. 95 (2007) 40-44
7. Okumura M., Shiono H., Minami M., Inoue M., Utsumi T., Kadota Y., and Sawa Y. Clinical and pathological aspects of thymic epithelial tumors. Gen. Thorac. Cardiovasc. Surg. 56 (2008) 10-16
8. Nakayama K.I., and Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin. Cell Dev. Biol. 16 (2005) 323-333
9. Strohmaier H., Spruck C.H., Kaiser P., Won K.A., Sangfelt O., and Reed S.I. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413 (2001) 316-322
10. Spruck C.H., Strohmaier H., Sangfelt O., Muller H.M., Hubalek M., Muller-Holzner E., Marth C., Widschwendter M., and Reed S.I. hCDC4 gene mutations in endometrial cancer. Cancer Res. 62 (2002) 4535-4539
11. Calhoun E.S., Jones J.B., Ashfaq R., Adsay V., Baker S.J., Valentine V., Hempen P.M., Hilgers W., Yeo C.J., Hruban R.H., and Kern S.E. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am. J. Pathol. 163 (2003) 1255-1260
12. Rajagopalan H., Jallepalli P.V., Rago C., Velculescu V.E., Kinzler K.W., Vogelstein B., and Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 428 (2004) 77-81
13. Kemp Z., Rowan A., Chambers W., Wortham N., Halford S., Sieber O., Mortensen N., von Herbay A., Gunther T., Ilyas M., and Tomlinson I. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 65 (2005) 11361-11366
14. Akhoondi S., Sun D., von der Lehr N., Apostolidou S., Klotz K., Maljukova A., Cepeda D., Fiegl H., Dofou D., Marth C., Mueller-Holzner E., Corcoran M., Dagnell M., Nejad S.Z., Nayer B.N., Zali M.R., Hansson J., Egyhazi S., Petersson F., Sangfelt P., Nordgren H., Grander D., Reed S.I., Widschwendter M., Sangfelt O., and Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67 (2007) 9006-9012
15. Malyukova A., Dohda T., von der Lehr N., Akhondi S., Corcoran M., Heyman M., Spruck C., Grander D., Lendahl U., and Sangfelt O. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 67 (2007) 5611-5616
16. Gu Z., Inomata K., Mitsui H., and Horii A. Promoter hypermethylation is not the major mechanism for inactivation of the FBXW7 β-form in human gliomas. Genes Genet. Syst. 83 (2008) 347-352
17. Onoyama I., Tsunematsu R., Matsumoto A., Kimura T., de Alborán I.M., Nakayama K., and Nakayama K.I. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T-cell differentiation and results in lymphomatogenesis. J. Exp. Med. 204 (2007) 2875-2888
18. FBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 207 (2007) 1825-1835
19. Kimura M., Abe T., Sunamura M., Matsuno S., and Horii A. Detailed deletion mapping on chromosome arm 12q in human pancreatic adenocarcinoma: identification of a 1-cM region of common allelic loss. Genes Chromosomes Cancer 17 (1996) 88-93
20. Gu Z., Inomata K., Ishizawa K., and Horii A. The FBXW7 β-form is suppressed in human glioma cells. Biochem. Biophys. Res. Commun. 354 (2007) 992-998
21. Sakurada A., Suzuki A., Sato M., Yamakawa H., Orikasa K., Uyeno S., Ono T., Ohuchi N., Fujimura S., and Horii A. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney and ovary. Jpn. J. Cancer Res. 88 (1997) 1025-1028
22. Xu S., Furukawa T., Kanai N., Sunamura M., and Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J. Hum. Genet. 50 (2005) 159-167